APP and Alzheimer disease: Indeed, due to its underlying mechanism (i.e., the accumulation of AβPP-derived iAβ to a certain range), AACD-CI can be treated by drugs reducing the influx of AβPP-derived iAβ and thus suppressing its rate of accumulation [1,2,3], whereas the same drugs would be completely ineffective in the treatment of AD-MCI, which is driven by iAβ produced independently from AβPP [1,2,3].